HEARTLINE HSM Genoa Cardiology Meeting - Aristea

More documents

Recommendations

Info

92 Raccolta dati Dati da Raccogliere a cura del 118 Di seguito vengono indicati alcuni dati temporali del servizio 118 che devono essere raccolti per poter eseguire il monitoraggio del progetto: • data e ora di insorgenza dei sintomi • data e ora chiamata al 118 • data e ora ecg • data e ora arrivo in Ps o emodinamica Sono da denire i tempi dalla porta del PS / emodinamica in poi Dati da raccogliere a cura dei DEA, PS: Dati anagraci (DOB, Sesso, Codice scale, altezza e peso) Fattori di rischio CV Eventi CV pregressi (infarto miocardico, ictus, CABG, scompenso cardiaco) Percorsi (118, autopresentazione PS Spoke, PS Hub, già in ospedale) Dati da raccogliere a cura dei Servizi di Emodinamica: Data e ora inizio sintomi, tipo sintomo, 1° contatto medico, 1° ecg diagnostico, porta primo ospedale, porta ospedale denitivo, inizio brinolisi, ingresso in emodinamica, coronarograa, gonaggio palloncino. Sede infarto, numero derivazioni ST elevato, recidiva eterosede, PA, FC, Classe Killip alla presentazione, arresto cardiaco. Terapia antiaggregante, tipo di terapia riperfusiva Estensione malattia coronarica, vaso colpevole, usso TIMI basale e nale, tecnica PTCA Eventi intraospedalieri, data dimissione Picco Tn - CKMB, FE alla dimissione, creatinina all’ingresso e di picco, Hb all’ingresso e nadir Eventi nel follow-up Bibliograa ESC/EACTS Guidelines European Heart Journal (2010) 1, 2 01–2 doi:10.109 /eurheartj/ehq277 -Fox K, Garcia MA, Ardissino D, et al. Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of <strong>Cardiology</strong>. Eur Heart J 2006;27:1 1–1 81. -Davies RF, Goldberg AD, Forman S, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization. Circulation 1997; 9 :20 7–20 . -Shaw LJ, Berman DS, Maron DJ, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 2008;117:128 –1291. -Pijls NH, van Schaardenburgh P, Manoharan G, et al. Percutaneous coronary intervention of functionally nonsignicant stenosis: -year follow-up of the DEFER Study. J Am Coll Cardiol 2007; 9:210 –2111. Allman KC, Shaw LJ, Hachamovitch R, et al. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002; 9:11 1–11 8. -Beanlands RS, Nichol G, Huszti E, et all. F-18- luorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol 2007; 0:2002–2012. -Fox KA, Clayton TC, Damman P, et ll. Long-term outcome of a routine versus selective invasive strategy in patients with non-STsegment elevation acute coronary syndrome a meta-analysis of individual patient data. J Am Coll Cardiol 2010; :2 –2 . -Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007;28:1 98–1660.
Yan AT, Yan RT, Tan M, et al. In-hospital revascularization and one-year outcome of acute coronary syndrome patients stratied by the GRACE risk score. Am J Cardiol 200 ;96:91 –916. -Lagerqvist B, Husted S, Kontny F, et al. -year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study. Lancet 2006; 68:998–100 . -Damman P, Hirsch A, Windhausen F et al,. -year clinicaloutcomes in the ICTUS (Invasive versus Conservative Treatment in Unstablecoronary Syndromes) trial a randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol 2010; :8 8–86 . -Fox KA, Poole-Wilson P, Clayton TC, et al. -year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA randomised trial. Lancet 200 ; 66:91 –920. -Giugliano RP, White JA, Bode C, et al. Early versus delayed, provisional eptibatide in acute coronary syndromes. N Engl J Med 2009; 60: 2176–2190. -Mehta SR, Granger CB, Boden WE, et al. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med 2009; 60:216 –217 . -Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 2 randomised trials. Lancet 200 ; 61:1 –20. -Kalla K, Christ G, Karnik R, et al. Implementation of guidelines improves the standard of care: Viennese registry on reperfusion strategies in ST-elevation myocardial infarction (Vienna STEMI registry).Circulation 2006;11 :2 98–2 0 . -Zahn R, Schiele R, Schneider S, et al. Decreasing hospital mortality between 199 and 1998 in patients with acute myocardial infarction treated with primary angioplasty but not in patients treated with intravenous thrombolysis. Results from the pooled data of the Maximal Individual Therapy in Acute Myocardial Infarction (MITRA) Registry and the Myocardial Infarction Registry (MIR). J Am Coll Cardiol 2000; 6:206 –2071. -Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 200 guideline update for percutaneous coronary intervention: a report of the American College of <strong>Cardiology</strong>/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006;11 :e166–e286. -Cantor WJ, Fitchett D, Borgundvaag B, et al. Routine early angioplasty after brinolysis for acute myocardial infarction. N Engl J Med 2009; 60:270 –2718. -Di Mario C, Dudek D, Piscione F, et al. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. Lancet 2008; 71: 9– 68. -Fernandez-Aviles F, Alonso JJ, Castro-Beiras A, et al. Routine invasive strategy within 2 hours of thrombolysis versus ischaemiaguided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial. Lancet 200 ; 6 :10 –10 . -Gershlick AH, Stephens-Lloyd A, Hughes S, et al. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med 200 ; :27 8–2768. -Bonnefoy E, Steg PG, Boutitie F, et al.Comparison of primary angioplasty and pre-hospital brinolysis in acute myocardial infarction (CAPTIM) trial: a -year follow-up. Eur Heart J 2009; 0:1 98–1606. -Widimsky P, Wijns W, Fajadet J et al. Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 0 countries. Eur Heart J 2010; 1:9 –9 7. -Boersma E. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital brinolysis in acute myocardial infarction patients. Eur Heart J 2006;27:779–788. -Nallamothu B, Fox KA, Kennelly BM, et al. Relationship of treatment delays and mortality in patients undergoing brinolysis and primary percutaneous coronary intervention. The Global Registry of Acute Coronary Events. Heart 2007;9 :1 2–1 . -Ellis SG, Tendera M, de Belder MA, et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008; 8:220 –2217. -Wijeysundera HC, Vijayaraghavan R, Nallamothu BK, et al. Rescue angioplasty or repeat brinolysis after failed brinolytic therapy for ST-segment myocardial infarction: a meta-analysis of randomized trials. J Am Coll Cardiol 2007; 9: 22– 0. -Busk M, Kaltoft A, Nielsen SS, et al. Infarct size and myocardial salvage after primary angioplasty in patients presenting with symptoms for ,12 h vs. 12–72 h. Eur Heart J 2009; 0:1 22–1 0. -Schomig A, Mehilli J,Antoniucci D, Ndrepepa G,. Mechanical ESC/EACTS Guidelines 2 9reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. JAMA 200 ;29 :286 –2872. -Hochman JS, Lamas GA, Buller CE, et al. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med 2006; :2 9 –2 07. -Steg PG, Thuaire C, Himbert D, et al. DECOPI (DEsobstruction COronaire en Post-Infarctus): a randomized multi-centre trial of occluded artery angioplasty after acute myocardial infarction. Eur Heart J 200 ;2 :2187–219 . -Weiss ES, Chang DD, Joyce DL, et al. Optimal timing of coronary artery bypass after acute myocardial infarction: a review of California discharge data. J Thorac Cardiovasc Surg 2008;1 : 0 – 11. -Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITONTIMI 8): double-blind, randomised controlled trial. Lancet 2009; 7 :72 –7 1. -Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomized double-blind study. Lancet 2010; 7 :28 –29 . -Huber K, Holmes DR Jr, van ’t Hof AW, et al. Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial. Eur Heart J 2010; 1;1708–1716. 9
Page 1:
HEARTLINE BOOK HEARTLINE HSM Genoa
Page 5 and 6:
Infarto Miocardico Acuto Esteso: c
Page 7 and 8:
La siopatologia cellulare dell’in
Page 9 and 10:
Sia in modelli di piccola che di gr
Page 11 and 12:
Citochine nell’infarto miocardico
Page 13 and 14:
mande ci viene probabilmente sugger
Page 15 and 16:
L’ecocontrastograa nello studio d
Page 17 and 18:
imaging molecolare con ECM, permett
Page 19 and 20:
mostrato che il miocardio ischemico
Page 21 and 22:
Trial Clinici sulla Terapia Cellula
Page 23 and 24:
nistra dopo riperfusione efcace. I
Page 25 and 26:
“Apical Ballooning Syndrome”: c
Page 27 and 28:
Fig. 3 ABS: ECG di presentazione in
Page 29 and 30:
Lesioni Coronariche critiche in sin
Page 31 and 32:
Infarto Miocardico Acuto: nuovi ori
Page 33 and 34:
(1.9%), indipendentemente dal tratt
Page 35 and 36:
I dati clinici a tre anni del Trial
Page 37 and 38:
Cardiopatia Ischemica: nuovi orizzo
Page 39 and 40:
Prasugrel Anche il Prasugrel è un
Page 41 and 42: Montalescot G, Wiviott SD, Braunwal
Page 43 and 44: che riunisce tutti gli ospedali con
Page 45 and 46: Costituzione di reti per lo shock c
Page 47 and 48: • Hub vs OspRER: due ricoveri, am
Page 49 and 50: Discussione Lo studio ha analizzato
Page 51: Nella TERZA FASE • Il progetto e
Page 54 and 55: Infarto miocardico acuto con ST sop
Page 56 and 57: 6 Nel registro STEMI del San Martin
Page 58 and 59: 8 Un terzo dei pz. proveniva dal 11
Page 60 and 61: 60 Outcome in base al rischio ed al
Page 62 and 63: 62 più rapidi rispetto a quelli ch
Page 64 and 65: 6 Bibliograa 1. Keeley EC, Boura JA
Page 66 and 67: 66 Infarto miocardico acuto con ST
Page 68 and 69: 68 Tabella 1 Tabella 2 Caratteristi
Page 70 and 71: 70 tanto è stato eliminato dal pro
Page 72 and 73: 72 Pazienti con STEMI suddivisi per
Page 74 and 75: 7 Flusso TIMI al termine della proc
Page 76 and 77: 76 Poche riessioni. I cittadini che
Page 78 and 79: 78 A tutt'oggi la diagnosi e la cur
Page 80 and 81: 80 Laboratorio di emodinamica • E
Page 82 and 83: 82 centro dove angiograa e PCI poss
Page 84 and 85: 8 (aneurisma del ventricolo sinistr
Page 86 and 87: 86 coci e con ampia area a rischio,
Page 88 and 89: 88 brinolisi e poi trasferiti per e
Page 90 and 91: 90 h. Reinfarto in sede elettrocard
Page 94 and 95: 9 -Stone GW, Witzenbichler B, Guagl
Page 96 and 97: 96 Tabella 2 Confronto modalità di
Page 98 and 99: 98 Le ragioni di questo fenomeno no
Page 100 and 101: 100 (“gMPS"), che consiste di mul
Page 102 and 103: 102 Figura 2 Tabella 1 Tabella 2 Da
Page 104 and 105: 10 Tabella 4 Tabella 5 che 6/12 ( 7
Page 106 and 107: 106 Tabella 8 Tabella 9 Le complica
Page 108 and 109: 108 Tabella 11 B Tabella 11 C Nella
Page 110 and 111: 110 Monitoraggio in remoto dei pazi
Page 112 and 113: 112 Percutaneous LAA Closure for St
Page 114 and 115: 11 Primary Safety Endpoint included
Page 116 and 117: 116 Fibrillazione Atriale: nuovi sc
Page 118 and 119: 118 Inibitori diretti del fattore X
Page 121 and 122: Conclusioni Sulla base degli studi
Page 123 and 124: Negli anni, il numero degli interve
Page 125 and 126: Via di accesso TS Centro PRE INT FI
Page 127 and 128: TF-AVI o TAVI in approccio transasc
Page 129 and 130: Gestione postoperatoria dei pazient
Page 131 and 132: • 1 insufcienza aortica paraprote
Page 133 and 134: Allegato 1 Modulo di presentazione
Page 135: Difetto del setto interventricolare
Page 138 and 139: 1 8 Indice pag. Infarto Miocardico
show all

HEARTLINE HSM Genoa Cardiology Meeting - Aristea

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?